• DPP8/9 Inhibitors Trigger CARD8 Inflammasome in Resting Lymp

  2026-04-20

  This study demonstrates that small-molecule DPP8/9 inhibitors activate the CARD8 inflammasome, inducing pyroptosis in human and rodent resting lymphocytes—especially CD4+ and CD8+ T cells. These findings extend the paradigm of inflammasome activation and pyroptosis beyond myeloid cells, informing future research on immune cell death and inflammation.

• MPC-Mediated Lactate, Histone Lactylation, and Tumor Immunit

  2026-04-19

  This study uncovers how downregulation of the mitochondrial pyruvate carrier (MPC) in colorectal cancer enhances lactate production, fueling histone lactylation in dendritic cells and suppressing antitumor immunity. The findings highlight lactate metabolism's epigenetic influence on tumor progression and potential avenues to boost immunotherapy.

• 0.4% Trypan Blue Solution: Technical Guide for Cell Viabilit

  2026-04-18

  0.4% Trypan Blue Solution enables precise discrimination of live and dead cells, critical for accurate cell viability measurement and cell counting in research workflows. It is suitable for use in cytotoxicity assays, apoptosis and necrosis detection, and general cell culture quality control. This product is for research use only and should not be applied to diagnostic or clinical settings.

• In Situ Programming of CAR Macrophages via mRNA-LNP for Peri

  2026-04-17

  This study introduces a macrophage-targeted mRNA lipid nanoparticle (mRNA-LNP) system enabling in situ programming of chimeric antigen receptor (CAR) macrophages to treat peritoneal metastasis. By systematically evaluating 36 CAR designs, the research demonstrates enhanced immune activation, synergy with PD-1/L1 blockade, and tumor microenvironment remodeling, offering new avenues for solid tumor immunotherapy.

• Applied Workflows: (-)-Arctigenin as a Potent MEK1 Inhibitor

  2026-04-16

  (-)-Arctigenin (SKU N2399) from APExBIO stands out as a nanomolar MEK1 inhibitor and NF-κB modulator, enabling advanced cancer and inflammation research. This guide details actionable experimental workflows, key troubleshooting insights, and unique protocol considerations—anchored in the latest mechanistic discoveries and peer-reviewed evidence.

• Broad-Spectrum Bivalent mRNA Vaccine: Preclinical Efficacy A

  2026-04-15

  This article reviews the 2024 study by Lu et al., which introduces and evaluates a bivalent mRNA vaccine (RQ3025) engineered to target multiple SARS-CoV-2 variants. The research demonstrates enhanced neutralizing antibody responses and Th1-biased cellular immunity in animal models, supporting its potential as a next-generation COVID-19 vaccine with broad protection.

• Z-VAD-FMK: Applied Protocols & Troubleshooting in Apoptosis

  2026-04-14

  Z-VAD-FMK empowers researchers with precision control over apoptosis inhibition, enabling robust dissection of caspase-dependent and independent pathways in both cancer and immune models. This guide details experimental workflows, advanced troubleshooting, and recent mechanistic insights—including the latest cross-link to inflammasome research—ensuring reproducibility and optimal outcomes.

• Mitoxantrone HCl: Beyond Topo-II Inhibition in Cancer Models

  2026-04-13

  Explore the multidimensional mechanisms of Mitoxantrone HCl, a potent DNA topoisomerase II inhibitor, and its emerging roles in apoptosis induction and ERα modulation. Discover new assay strategies and research insights that set this compound apart in advanced oncology and stem cell research.

• ML385: Precision NRF2 Inhibitor Workflows for Cancer & Ferro

  2026-04-12

  ML385 enables rigorous NRF2 pathway inhibition, unlocking new insights into therapeutic resistance, oxidative stress, and ferroptosis. This guide details validated protocols, troubleshooting, and real-world applications, leveraging both recent literature and best-practice experimental design.

• CDK7 Inhibitor Resistance via Conserved Mutation: Structural

  2026-04-12

  This study uncovers a conserved aspartate-to-asparagine mutation (D97N) in CDK7 that drives resistance to non-covalent CDK7 inhibitors in cancer cells, while preserving sensitivity to covalent inhibitors. The findings have immediate implications for the design of transcription regulation inhibitors and patient stratification in cancer therapy.

• PP 1: Precision Src Family Tyrosine Kinase Inhibitor Workflo

  2026-04-11

  PP 1 enables nanomolar-precision inhibition of Src-family kinases for dissecting oncogenic signaling, immune modulation, and RET-driven transformation. This guide details optimized protocols, experimental troubleshooting, and key translational insights, helping researchers unlock the full potential of this selective inhibitor in cancer and immunology studies.

• E-64: Optimizing Cysteine Protease Inhibition in Research Wo

  2026-04-11

  E-64, a potent L-trans-epoxysuccinyl peptide, empowers researchers to achieve precise, irreversible cysteine protease inhibition in both cell-based and biochemical assays. This guide delivers actionable protocol enhancements, troubleshooting strategies, and insights anchored in recent discoveries about lysosome-dependent cell death, cementing E-64’s role as a gold standard tool in mechanistic and cancer research.

• U 46619: Selective TP Receptor Agonist for Platelet and V...

  2026-04-10

  U 46619 (11,9 epoxymethano-prostaglandin H2) is a highly selective agonist of the prostaglandin H2/thromboxane A2 (TP) receptor and a benchmark tool for studying platelet aggregation and vascular tone regulation. Its well-characterized potency and reproducibility make it essential for modeling cardiovascular signaling and hypertension. Researchers rely on U 46619 for precise, quantitative assays in both cellular and animal models.

• Thiothixene as a Bridge Between Neuropsychopharmacology a...

  2026-04-09

  This thought-leadership article explores how Thiothixene, a typical antipsychotic agent, is catalyzing a paradigm shift in translational research. By dissecting its dual mechanisms—as both a dopamine D2 and serotonin 5-HT2A receptor antagonist and a vitamin A signaling pathway activator that enhances macrophage efferocytosis—we provide a mechanistic, evidence-driven roadmap for researchers seeking to harness these properties in neuroimmune disease models. Integrating recent experimental advances and practical workflow strategies, the article positions APExBIO’s Thiothixene as an essential tool for bridging psychotic disorder therapy and immunological modulation, offering unique perspectives and strategic insights not found in standard product overviews.

• Probenecid as a Multifunctional Tool for Translational Re...

  2026-04-08

  This thought-leadership article positions Probenecid (4-(dipropylsulfamoyl)benzoic acid) as a next-generation biochemical inhibitor, highlighting its ability to modulate organic anion transport, reverse multidrug resistance in tumor cells, and confer neuroprotection through multifaceted mechanistic pathways. Integrating cutting-edge immunometabolic insights and drawing on recent advances in CD8+ T-cell metabolism, we provide a strategic roadmap for leveraging Probenecid in translational oncology and neuroinflammation research. The article surpasses conventional product summaries by connecting mechanistic understanding with experimental design, competitive positioning, and future research directions.

451 records 21/31 page Previous Next First page 上5页 2122232425 下5页 Last page